SCHEMBL734818

SCHEMBL734818

CC1C(=O)NCCN1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.54
AR P10275 8/20 0.50
LMNA P02545 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
CYP3A4 P08684 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CYP1A2 P05177 2/20 0.50
PGR P06401 2/20 0.50
CYP2C9 P11712 2/20 0.50
TSHR P16473 2/20 0.50
CYP2C19 P33261 2/20 0.50
TP53 P04637 1/20 0.50
CYP2D6 P10635 1/20 0.50
ALOX12 P18054 1/20 0.50
NFKB1 P19838 1/20 0.50
RAB9A P51151 1/20 0.50
PDE4D Q08499 1/20 0.50
MAPT P10636 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735198 0.81 BCL2A1 (0.43) ARRAB9ABCL2A1
SCHEMBL734459 0.81 BCL2A1 (0.54) ARSMN1; SMN2CYP3A4MEN1KMT2A
SCHEMBL27811988 0.77 SIRT6 (0.51) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL2795693 0.76 SIRT6 (0.58) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL2795699 0.76 SIRT6 (0.58) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL18540958 0.74 SIRT6 (0.52) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL6860876 0.74 SIRT6 (0.52) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL6860868 0.74 SIRT6 (0.52) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL18540933 0.74 SIRT6 (0.52) SIRT6ARLMNASMN1; SMN2CYP3A4
SCHEMBL6860871 0.74 SIRT6 (0.52) SIRT6ARLMNASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 SIRT6 1933/4885AR 811/4885LMNA 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.